Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for obe-cel (AUTO1) (CD19) in Systemic lupus erythematosus. The expected timing is based on the latest available company guidance and may change.
05/14/26:- CARLYSLE supported 50M-cell Phase 2 dose; longer-term SLE data expected by YE 2026. 08/11/26:- CARLYSLE SLE data submitted for ACR Q4 2026; longer follow-up expected by YE 2026.
Verification
Confirm timing and program details against the company announcement or filing.